智通财经网·2025-11-14 15:48Core Viewpoint - Mangoceuticals (MGRX.US) experienced significant stock volatility following a retraction of its previous announcement regarding partnerships with Eli Lilly (LLY.US) and Novo Nordisk (NVO.US) [1] Group 1: Stock Performance - The stock initially dropped approximately 13% in pre-market trading but later recovered to a slight increase of 2.94%, closing at $1.225 [1] Group 2: Partnership Announcement - On Thursday, Mangoceuticals claimed to have established partnerships with Eli Lilly and Novo Nordisk to provide GLP-1 weight loss medications through its MangoRx Direct and PeachesRx Direct programs [1] - This announcement was quickly contradicted as Eli Lilly publicly denied any partnership, and Novo Nordisk did not confirm the collaboration [1]